Browse Articles

Discover research articles across all indexed journals

Event-free survival with adjuvant selpercatinib in stage IB-IIIA <i>RET</i> fusion-positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trial.

Journal of Clinical Oncology Jonathan W. Goldman, Xuening Yang, Maximilian Hochmair et al. Jun 10, 2026 DOI: 10.1200/jco.2026.44.17_suppl.lba3

LBA3 Background: Selpercatinib, a highly selective, potent and brain-penetrant RET inhibitor, is approved for RET fusion-positive ( RET+ ) advanced/metastatic non-small cell lung cancer (NSCLC). RET-directed therapy has yet to be examined in patients (pts) with stage IB-IIIA RET+ NSCLC, where recurrence rates after definitive therapy remain high, and no adjuvant targeted therapy is approved. Here, we report the efficacy and safety of selpercatinib vs placebo in this population. Methods: LIBRETTO-432 (NCT04819100) is a placebo-controlled, double-blind, phase 3 randomized (1:1) trial of selpercatinib 160mg BID vs placebo for up to 3 years in pts with stage IB-IIIA RET+ NSCLC after definitive locoregional treatment. Primary endpoint was investigator-assessed event-free survival (EFS) in stage II-IIIA pts. Secondary endpoints were investigator-assessed EFS in all randomized pts (overall population, stage IB-IIIA), EFS by blinded independent central review (BICR), overall survival and safety. Crossover from placebo to selpercatinib was allowed upon disease recurrence. Results: In total, 151 pts were randomized (selpercatinib n=75; placebo n=76) and baseline characteristics were balanced across treatment arms. Median follow-up was 24 months for selpercatinib and 27 months for placebo. At the preplanned efficacy analysis, selpercatinib demonstrated significantly improved EFS in pts with stage II-IIIA disease (n=109), HR 0.172 (95% CI: 0.058, 0.509; p=0.0003). The median EFS was not reached for selpercatinib vs 31.8 months for placebo (4 vs 19 EFS events, respectively). EFS by BICR, HR=0.125 (95% CI: 0.028, 0.552; p=0.0011), was consistent with investigator-assessed EFS. The 2-year EFS rate was 91.5% for selpercatinib vs 61.1% for placebo. In the overall population (n=151), error-controlled EFS HR was 0.165 (95% CI: 0.056, 0.485; p=0.0002), and median EFS was not reached on either treatment arm. Adverse events (AEs) with selpercatinib were comparable to those reported in metastatic RET + NSCLC. The most common AEs were increased ALT/AST. Only 3 deaths were observed, all occurred in the placebo arm due to the study disease. No pts died during assigned study treatment. Conclusions: Selpercatinib achieved a statistically significant and clinically meaningful improvement in event-free survival compared to placebo in patients with early-stage RET+ NSCLC. These data add to the body of evidence for targeted therapy, including EGFR and ALK inhibitors, in the adjuvant NSCLC setting and underscore the importance of comprehensive genomic testing at diagnosis of NSCLC across disease stages to inform optimal therapeutic decision-making. Clinical trial information: NCT04819100 .

Aqueous-Based Biomimetic Porphyrin-Catalyzed Surface Oxidation of Polyethylenes for Enhanced 3D-Printability

Journal of the American Chemical Society Haonan Zhao, Danwei Zhang, Wei Wei Loh et al. Jun 10, 2026 DOI: 10.1021/jacs.6c02938

Reduced sensitivity to tactile stimuli associated with physical and mental disorders: A monozygotic twin study

Scientific Reports Saito Sakaguchi, Yusuke Morito, Masashi Konyo et al. Jun 10, 2026 DOI: 10.1038/s41598-026-56098-0

Abstract Tactile sensitivity is crucial for perceiving subtle external stimuli and maintaining a high quality of life. While individual differences in tactile sensitivity are influenced by local factors, such as skin condition and nerve density, the relationships between tactile sensitivity and systemic factors, such as physical and mental health, remain unclear. This study investigated how systemic conditions are related to tactile sensitivity, excluding genetic influences, by analyzing 25 pairs of monozygotic (MZ) twins. Tactile thresholds were measured using suction stimuli on the cheek and compared with psychophysiological data from questionnaires and objective measurements. The results revealed that 18 twin pairs presented similar thresholds, indicating a genetic influence. However, in 7 twin pairs with differing thresholds, reduced tactile sensitivity was associated with greater physical and mental disorders, such as fatigue and anxiety. These findings suggest that tactile sensitivity is influenced not only by genetic factors but also by systemic health conditions that are shaped by lifestyle. Furthermore, impaired tactile sensitivity may reflect broader physical and mental health issues, making it a potential marker for preventive health interventions. This study provides insights into the complex interplay between tactile perception and systemic health, paving the way for tactile interventions aimed at enhancing the quality of life.

Ultra-low-dose immunotherapy plus oral metronomic chemotherapy versus paclitaxel-carboplatin in platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma: A randomized phase III trial.

Journal of Clinical Oncology Minit Jalan Shah, Vanita Noronha, Nandini Sharrel Menon et al. Jun 10, 2026 DOI: 10.1200/jco.2026.44.17_suppl.lba6007

LBA6007 Background: Standard first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) includes platinum-based chemotherapy (PBC) combined with pembrolizumab or cetuximab; however, these regimens remain inaccessible for many patients globally, particularly in resource-limited settings. Triple oral metronomic chemotherapy combined with ultra-low-dose immunotherapy (TMC-I) has demonstrated promising activity and tolerability in earlier studies. We conducted a randomized phase III trial comparing TMC-I with PBC (paclitaxel and carboplatin) in patients with R/M-HNSCC receiving first-line palliative therapy. Methods: In this open-label, multicenter, phase III trial conducted at two centers, 422 patients with R/M-HNSCC were randomized (1:1) to receive paclitaxel 175 mg/m² plus carboplatin AUC 6 every 3 weeks (Arm-A) or TMC-I (oral methotrexate 9 mg/m² weekly, celecoxib 200 mg twice daily, erlotinib 150 mg daily, and nivolumab 20 mg IV every 3 weeks) (Arm-B). Treatment continued until disease progression or unacceptable toxicity. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), safety, and quality of life (QoL). The planned sample size of 422 patients (211 per arm) provided 80% power with a two-sided α of 0.05. The trial was registered with the Clinical Trials Registry–India (CTRI/2024/01/061661). Results: The median age was 49.5 years (IQR 42–58), 85.5% were male, 78.9% had oral tobacco use, 76.3% had oral cavity primaries, 25.6% had metastatic disease, and 30.6% had ECOG performance status 2. After a median follow-up of 10.8 months (95% CI 8.1–13.6) in Arm-A and 11.9 months (95% CI 10.3–13.4) in Arm-B, the primary endpoint of OS was significantly improved with TMC-I compared with PBC. Twelve-month OS was 46% versus 23%, and six-month OS was 69% versus 52% (p &lt; 0.001). Median OS was 10.3 versus 6.2 months (HR 0.565, 95% CI 0.439–0.728; p &lt; 0.001). Median PFS was 5.5 versus 2.7 months (HR 0.465, 95% CI 0.371–0.582; p &lt; 0.001). ORR was higher with TMC-I than with PBC (53.4% vs 24.1%; p &lt; 0.001), with fewer grade ≥3 adverse events (34.1% vs 46.4%; p = 0.010). No treatment-related deaths were observed, and patient-reported QoL was preserved with TMC-I. Conclusion: TMC-I significantly improved survival outcomes and response rates while reducing severe toxicity and preserving QoL compared with PBC. At approximately USD 230 per month, TMC-I represents a promising and cost-effective first-line treatment option for patients with R/M-HNSCC. Clinical trial information: CTRI/2024/01/061661.

Insights into the Debated Lyase Mechanism of Bifunctional DNA Glycosylases from MD and QM/MM MD Simulations: The Case Study of DNA Oxidative Damage Repair by Human 8-Oxoguanine DNA Glycosylase

Journal of the American Chemical Society Dylan J. Nikkel, Trinity K. Deak, Stacey D. Wetmore Jun 10, 2026 DOI: 10.1021/jacs.6c07534

The integrated to developmental stress response (ISR-DASR) shift reveals a functional transition from cellular to stem cell organismal adaptation

Scientific Reports Ximena Ruden, Campbell Coddington, Lynessa Asplund et al. Jun 10, 2026 DOI: 10.1038/s41598-026-55295-1

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial.

Journal of Clinical Oncology Chen Zhiwei, Fang Yang, Yongzhong Luo et al. Jun 10, 2026 DOI: 10.1200/jco.2026.44.17_suppl.lba4

LBA4 Background: In the prespecified interim analysis of progression-free survival (PFS) from the HARMONi-6 study, ivonescimab combined with chemotherapy significantly improved PFS compared with tislelizumab plus chemotherapy in patients with previously untreated advanced squamous NSCLC(sq-NSCLC). Here we report the results of the prespecified overall survival (OS) analysis. Methods: Patients with previously untreated stage III-IV sq-NSCLC were randomly assigned (1:1) to receive ivonescimab 20 mg/kg every 3 weeks (Q3W) or tislelizumab 200 mg Q3W, each in combination with paclitaxel (175 mg/m²) and carboplatin (AUC 5) for 4 cycles, followed by maintenance ivonescimab or tislelizumab monotherapy. Randomization was stratified by disease stage (IIIB/IIIC versus IV) and PD-L1 tumor proportion score (TPS; ≥1% versus &lt;1%). The primary endpoint was PFS assessed by independent radiographic review committee per RECIST v1.1. OS was a key secondary endpoint and was hierarchically tested using a closed sequential testing procedure. PFS was tested first at one-sided α level of 0.025, OS was tested at the same α only after statistical significance for PFS was established. This analysis represents the first planned OS analysis with an efficacy boundary of one-sided P=0.0049. Results: A total of 532 patients were randomly assigned (n=266 per arm). As of February 27, 2026, at a median follow-up of 21.4 months, ivonescimab plus chemotherapy significantly improved OS compared with tislelizumab plus chemotherapy. Median OS was 27.9 months (95% CI, 27.89 to NE) with ivonescimab plus chemotherapy versus 23.7 months (95% CI, 20.11 to NE) with tislelizumab plus chemotherapy (hazard ratio [HR], 0.66; 95% CI, 0.50 to 0.87; one-sided P =0.0017), meeting the prespecified boundary (P&lt;0.0049) for statistical significance.The OS benefit was consistent across prespecified subgroups. Among patients with PD-L1 TPS &lt;1%, median OS was NE versus 18.6 months (HR, 0.64; 95% CI, 0.43 to 0.96). Among patients with PD-L1 TPS≥1%, median OS was NE versus 27.3 months (HR, 0.68; 95% CI, 0.46 to 0.99). The safety profile of ivonescimab plus chemotherapy was manageable and consistent with prior reports, with no new safety signals observed. Conclusion: Ivonescimab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS compared with tislelizumab plus chemotherapy in previously untreated patients with advanced sq-NSCLC. Notably, ivonescimab plus chemotherapy is the first regimen to show clinical superiority over an active PD-1 inhibitor control arm in the first-line setting. The dual-targeted approach of ivonescimab delivers improved survival outcomes with a favorable risk-benefit profile, establishing a compelling new standard of care in the management of advanced sq-NSCLC. Clinical trial information: NCT05840016 .

Structural and Spectroscopic Basis for Catalysis by a Class C Radical <i>S</i> -Adenosylmethionine Methylase Involved in Nosiheptide/Nocathiacin Biosynthesis

Journal of the American Chemical Society Bo Wang, Hayley L. Knox, Nicholas J. York et al. Jun 10, 2026 DOI: 10.1021/jacs.6c03999

Complete mitochondrial genome sequence of Koelreuteria paniculata (Sapindaceae) and comparative analysis within the family Sapindaceae

Scientific Reports Young-Ho Ha, Jei-Wan Lee, Ji-Young Ahn Jun 10, 2026 DOI: 10.1038/s41598-026-53883-9

Adjuvant aspirin for stage III colorectal cancer after curative resection: Primary analysis of the randomized double-blind placebo-controlled phase III trial (EPISODE-III: JCOG1503C).

Journal of Clinical Oncology Atsuo Takashima, Yasumitsu Hirano, Manabu Shiozawa et al. Jun 10, 2026 DOI: 10.1200/jco.2026.44.17_suppl.lba3508

LBA3508 Background: Observational studies suggest aspirin benefits in colorectal cancer (CRC), but adjuvant evidence remains limited. In unselected populations, phase III trials have not shown a clear benefit, while biomarker-selected studies suggest a benefit in PI3K-altered tumors. EPISODE-III evaluates whether low-dose aspirin improves disease-free survival (DFS) in unselected stage III CRC receiving standard adjuvant chemotherapy. Methods: EPISODE-III is a multi-institutional, two-arm, randomized, double-blind, placebo-controlled phase III trial at 36 institutions in Japan. Eligible patients (20–80 years; ECOG PS 0–1) with histologically confirmed, R0-resected stage III adenocarcinoma from the cecum to upper rectum (lower rectum excluded) after D2/D3 lymph node dissection were randomized 1:1 to low-dose aspirin (100 mg once daily) or matched placebo for 3 years, in addition to standard adjuvant chemotherapy (capecitabine, mFOLFOX6, or CAPOX). Randomization was balanced by institution, sex, stage (IIIA/IIIB/IIIC), and planned oxaliplatin use. The primary endpoint was DFS (event: relapse, second cancer, or death). Secondary endpoints included overall survival (OS), relapse-free survival (RFS), relative dose intensity (RDI) of aspirin and placebo, and safety. The planned sample size was 880 (279 DFS events), providing 80% power with a one-sided α = 0.05 to detect hazard ratio (HR) of 0.741 (assumed 3-year DFS 74% vs. 80%). Results: Between Mar 2018 and Oct 2022, 882 patients (placebo 442; aspirin 440) were enrolled. At the data cutoff (Oct 2025), the median follow-up for all randomized patients was 4.0 years, with 231 DFS events (placebo 124; aspirin 107). Baseline characteristics were balanced (median age 65 vs. 64 years; pIIIA/IIIB/IIIC 19/63/18% vs. 19/62/19%; planned oxaliplatin-containing regimen 70% vs. 71%). Three-year DFS was 75.4% with placebo and 78.8% with aspirin (+3.4%); the primary endpoint was not met (HR 0.84, 95% CI 0.65–1.09; one-sided p=0.0987). DFS, RFS, and OS are shown in the Table. Grade ≥3 adverse events were similar between arms, and grade ≥3 aspirin-related adverse events were &lt;1% (lower GI bleeding n=4). One treatment-related death was observed in the aspirin arm during chemotherapy (ischemic heart disease). RDI was high and comparable (median 98.6% in both arms). Conclusion: Low-dose aspirin added to standard adjuvant chemotherapy did not significantly improve DFS in unselected stage III CRC. However, a numerical DFS improvement with good tolerability was observed. Exploratory biomarker analyses including PI3K/PIK3CA are ongoing and will inform a planned collaborative meta-analysis of randomized trials. Clinical trial information: jRCTs031180009. 3-year (%)placebo vs. aspirin HR (95% CI) P (one-sided) DFS 75.4 vs. 78.8 0.84 (0.65–1.09) 0.0987 RFS 77.2 vs. 79.5 0.87 (0.66–1.14) - OS 96.6 vs. 95.2 1.02 (0.65–1.60) -

Pronounced Neuroplasticity in the Primary Visual Cortex of the 13-Lined Ground Squirrel during Hibernation

Journal of Neuroscience Allison Fultz, Carlos A. Mejias-Aponte, Christina Jacob et al. Jun 10, 2026 DOI: 10.1523/jneurosci.0077-26.2026

Hibernating animals can show neuroplasticity throughout the hibernation season. In ground squirrels, decreased dendritic arborization in the hippocampus, somatosensory cortex, and thalamus during deep hibernation (“torpor”) suggests that this neuroplasticity is a brain-wide phenomenon. However, the degree to which neuroplasticity occurs in the visual system is not clear. While transient retinal changes have been reported during torpor, neuroplasticity beyond the retina remains unknown. Here, we characterized hibernation-related neuroplasticity in the primary visual cortex (V1), the first cortical area to receive visual information, in the 13-lined ground squirrel ( Ictidomys tridecemlineatus ). We compared neuronal morphology in Golgi-stained samples from male and female hibernating or nonhibernating squirrels. For the hibernating squirrels, the brain tissue was sampled during two different epochs: torpor and intertorpor arousal. Dendritic arborization decreased during torpor in V1 layer 2/3 pyramidal neurons, manifesting as decreases in dendritic length, number, and complexity. These changes fully reversed during intertorpor arousal, indicating that on average dendritic arbors grew by 0.75 mm (65%) over ∼1.5 h. No morphological differences between hibernating and nonhibernating squirrels were apparent when compared 6 months after the hibernation season. We also found no neuroplastic changes in V1 layer 4 spiny stellate neurons, unlike in this cell type in the somatosensory cortex. Together, this revealed, for the first time, hibernation-related neuroplasticity in V1 in support of a brain-wide mechanism but with area-specific differences. The speed and magnitude of this naturally occurring neuroplasticity could make ground squirrel V1 a powerful translational model system for conditions requiring neuroplasticity, such as recovery from stroke.

In the wake of the Hayli Gubbi eruption

Scientific Reports Alexander Ukhov, Sateesh Masabathini, Marianthi Pateraki et al. Jun 10, 2026 DOI: 10.1038/s41598-026-56967-8

Anbenitamab plus albumin-bound docetaxel (nab-docetaxel) ± carboplatin (Cb) versus trastuzumab and pertuzumab plus docetaxel (THP) ± Cb as neoadjuvant therapy for HER2-positive early or locally advanced breast cancer: A randomized, open-label, multicenter, phase 3 trial.

Journal of Clinical Oncology Zhi-Ming Shao, Peng Ji, Tong Liu et al. Jun 10, 2026 DOI: 10.1200/jco.2026.44.17_suppl.lba660

LBA660 Background: THP ± Cb represent the standard neoadjuvant treatment for HER2-positive breast cancer. Despite achieving total pathological complete response (tpCR) rates between 39.3% and 56.0%, there remains a clinical need to further improve outcomes, as tpCR is strongly correlated with long-term survival. Anbenitamab (KN026) is a novel biparatopic antibody targeting HER2 domains II and IV. This phase 3 study (NCT06747338) compared the efficacy and safety of an Anbenitamab-based regimen to the standard-of-care THP± Cb regimen in the neoadjuvant setting. Methods: Patients with HER2-positive early or locally advanced breast cancer were randomized 1:1 to receive 6 cycles of either Anbenitamab plus nab-docetaxel ± Cb [Anbenitamab arm] or trastuzumab, pertuzumab, and docetaxel ± Cb [THP ± Cb arm]. Randomization was stratified by clinical stage, hormone receptor status, and planned carboplatin use. The primary endpoint was tpCR (ypT0/is, ypN0) as assessed by a Blinded Independent Review Committee (BIRC). Results: A total of 521 patients were randomized. The study met its primary endpoint, with a significantly higher tpCR rate in Anbenitamab arm compared to THP ± Cb arm (62.4% [95% CI: 56.2–68.2] vs. 51.2% [95% CI: 44.9–57.4]). The stratified difference in tpCR was 11.4% (95% CI: 3.2–19.6); one-sided P = 0.0036). Consistent results were observed for investigator assessed tpCR (63.9% [95% CI: 57.8–69.7] vs. 51.2% [95% CI: 44.9–57.4], one-sided P = 0.0011). Similar improvements in BIRC-tpCR were observed across all prespecified subgroups, including those defined by hormone receptor status, clinical stage, and planned carboplatin use. BIRC-assessed breast pCR was also significantly higher in Anbenitamab arm (64.6% vs 55.0%, one-sided P = 0.0099). The overall incidence of treatment emergent adverse events (TEAEs) was 98.5% in Anbenitamab arm versus 98.8% in THP ± Cb arm. Grade ≥3 TEAE rates were similar (29.3% vs 28.3%). Most common Grade ≥3 TEAEs were neutropenia (11.4 % vs 10.9%) and leukopenia (7.6% vs 8.5%). TEAEs leading to interruption of any study drug occurred in 5.7% vs 7.4% of patients. Permanent discontinuations due to TEAEs occurred in 4.9% vs 3.5% of patients. Safety profiles were primarily hematologic and gastrointestinal toxicities, consistent with known safety profiles of respective single agents, and no new safety signal was observed. Conclusions: Anbenitamab plus nab-docetaxel ± Cb significantly improved tpCR rate compared with standard of care as neoadjuvant therapy in patients with early or locally advanced HER2-positive breast cancer, with a manageable safety profile. These results support Anbenitamab-based regimen as a potential new standard of care. Clinical trial information: NCT06747338 .

Tracing the Origin of Driving Force of Photoinduced Interfacial Electron Transfer Reaction by Colocated Scanning Electrochemical Microscopy

Journal of the American Chemical Society Wenjing Nan, Xuan Liu, Jiayang Lin et al. Jun 10, 2026 DOI: 10.1021/jacs.5c19712

Marker-trait association analysis revealed loci linked to salinity tolerance in a worldwide collection of safflower

Scientific Reports Fatemeh Saeidnia, Mohammad Mahdi Majidi, Fatemeh Ebrahimi et al. Jun 10, 2026 DOI: 10.1038/s41598-026-56459-9

Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial

Journal of Clinical Oncology Patrick Y. Wen, Donald A. Berry, Meredith B. Buxton et al. Jun 10, 2026 DOI: 10.1200/jco-26-01027

Atomic Imaging of Ion-Triggered Flexibility and Local Electric Field Response in Zeolite Rings

Journal of the American Chemical Society Qiang Chen, Zhao-Bin Ding, Pengfei Cao et al. Jun 10, 2026 DOI: 10.1021/jacs.5c22979

Modulation of Neuronal Ensembles Switches Memory Flexibility via Hippocampal Network Resynchronization

Journal of Neuroscience Chao Liu, Qingna Hao, Yang Cui et al. Jun 10, 2026 DOI: 10.1523/jneurosci.2340-25.2026

Engram cells are formed during learning and store memory information. However, little is known about the modulation of engram cells on time-dependent memory flexibility. Employing a male mouse model, we demonstrated that a temporal factor dictates the memory state, driving either pattern separation or pattern completion. Reengagement of engram cells in the dentate gyrus (DG) during memory retrieval in altered contexts was higher during pattern separation than during pattern completion, concomitant with a time-dependent reduction in synaptic transmission. Specific activation of DG engrams promoted pattern separation, whereas their inhibition accelerated pattern completion. Furthermore, activating DG engrams not only prolonged sharp-wave ripple (SWR) duration and enhanced theta–gamma phase–amplitude coupling (PAC) in CA1 but also strengthened cross-regional theta (DG) –gamma (CA1) PAC and gamma (DG–CA1) coherence. Conversely, their inhibition resulted in diminished SWR durations, attenuated these PACs, and reduced DG–CA1 gamma coherence. Finally, elevated Rac1 activity within DG engrams accelerated pattern completion, while reduced activity facilitated pattern separation. These findings show that engram cells drive time-dependent memory flexibility via neural network resynchronization.

Controlled polymerization of methyl acrylate in the presence of copper MOF (Basolite®C300): strategy and characterization

Scientific Reports Edina Rusen, Cristina Stavarache, Aurel Diacon et al. Jun 10, 2026 DOI: 10.1038/s41598-026-57663-3

Durvalumab monotherapy versus active monitoring for resected primary renal cell carcinoma in RAMPART: An international, phase 3, randomized controlled trial.

Journal of Clinical Oncology James M.G. Larkin, Thomas Powles, Elena Frangou et al. Jun 10, 2026 DOI: 10.1200/jco.2026.44.17_suppl.lba4511

LBA4511 Background: RAMPART is evaluating one year of immune checkpoint inhibitor therapy versus active monitoring in patients with renal cell carcinoma (RCC) at intermediate or high risk of recurrence following nephrectomy according to the Leibovich Score (LS) or following complete resection of limited metastatic disease (M1NED). The trial has already shown that durvalumab and tremelimumab improves disease free survival (DFS), largely driven by effect in the higher risk population (LS high and M1NED). Methods: We recruited participants (pts) from 80 sites and randomised them in a 3:2:2 ratio between: Arm A, active monitoring; Arm B, 1 year (13 cycles) of durvalumab (1500mg); or Arm C, 1 year (13 cycles) of durvalumab (1500mg) plus tremelimumab (75mg, cycles 1 and 2 only). Based on the results of the KEYNOTE-564 trial, pembrolizumab became a treatment option for many of the patients who would be eligible for RAMPART, and recruitment was stopped earlier than planned. We revised the RAMPART design without knowledge of the accumulating trial results. In the modified design there is 80% power to detect a hazard ratio (HR) for the primary outcome of DFS of 0.60 for arm B vs. A, and of 0.55 for arm C vs. A. The overall familywise type I error rate remains strongly controlled at 2.5% (1-sided) across all primary analyses. The analysis plan includes a pre-specified, pre-powered analysis by risk of relapse. Results: Between October 2018 and June 2023, we randomised 790 pts (340, 225, and 225 to arms A, B, and C) from the UK (70%), France (21%), Australia (5%) and Spain (4%). Baseline characteristics were balanced across arms. Median age (range) was 60 (22, 83) years, 72% were male, 84% clear cell histology. Treatment with durvalumab (Arm B) was associated with a 26% relative reduction in the hazard of disease recurrence or death; conventional statistical significance was not reached (DFS HR = 0.74; 95% CI 0.53–1.04; 1p=0.041). DFS at 3 years was 78% with Arm B vs 72% Arm A. In the pre-specified DFS analysis by risk of recurrence, no evidence of a treatment-by-subgroup interaction was observed. This contrasts with the results of Arm C vs Arm A. Table 1 summarises results of the two RAMPART primary analyses. Exposure to treatment, safety, quality of life, overall survival and efficacy in non-clear cell subtypes will be presented. Conclusion: In RAMPART, durvalumab plus tremelimumab was associated with a statistically significant improvement in DFS, which was not observed with durvalumab monotherapy. Clinical trial information: NCT03288532 . Primary analysis results. Arm C vs A Arm B vs A All pts N=565; HR=0.65, 95%CI 0.45-0.93 N=565; HR=0.74, 95 CI 0.53–1.04 Higher Risk N=311; HR=0.52, 95%CI 0.34-0.80 N=312, HR=0.77, 95%CI 0.53–1.12 Intermediate Risk N=254, HR= 1.19, 95% CI 0.61-2.32 N=253, HR= 0.64, 95%CI 0.30–1.34 Test for Interaction HR=0.43, 95%CI 0.19-0.95 HR=1.20, 95%CI 0.52-2.74